Fido Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-11-2024
- Paid Up Capital ₹ 5.00 M
as on 03-11-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.60 Cr
as on 03-11-2024
- Revenue 72.47%
(FY 2023)
- Profit 98.02%
(FY 2023)
- Ebitda 138.19%
(FY 2023)
- Net Worth 55.10%
(FY 2023)
- Total Assets 98.85%
(FY 2023)
About Fido Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹5.60 Cr.
Parbhat Singh, Tejal Vispute, and Ritu Singh serve as directors at the Company.
- CIN/LLPIN
U24230HR2020PTC085725
- Company No.
085725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Fido Pharma Private Limited offer?
Fido Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Bird Food, Poultry & Animal Food, Fish Foods, Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients), Organic and Inorganic Solvents, Ketones, Fertilizers and Soil Additives, Plant Growth Promoters.
Who are the key members and board of directors at Fido Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parbhat Singh  | Director | 04-Mar-2020 | Current |
| Tejal Vispute | Director | 04-Mar-2020 | Current |
| Ritu Singh | Director | 30-May-2023 | Current |
Financial Performance of Fido Pharma.
Fido Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 72.47% increase. The company also saw a substantial improvement in profitability, with a 98.02% increase in profit. The company's net worth Soared by an impressive increase of 55.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fido Pharma?
Unlock access to Fido Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Feb 2024 | ₹5.00 Cr | Open |
Hdfc Bank Limited Creation Date: 28 Dec 2023 | ₹6.00 M | Open |
How Many Employees Work at Fido Pharma?
Unlock and access historical data on people associated with Fido Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fido Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fido Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
